KRT13 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%.
Images
Key facts
- Cell type
- A-431
- Species or organism
- Human
- Tissue
- Skin
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%
Alternative names
47 kDa cytokeratin, CK-13, Cytokeratin-13, K13, K1C13_HUMAN, KRT13, Ka13, Keratin, Keratin-13, Krt-1.13, Krt1-13, MGC161462, MGC3781, Type I keratin Ka13, WSN2, keratin type I cytoskeletal 13, type I cytoskeletal 13
What's included?
Recommended products
KRT13 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%.
Key facts
- Cell type
- A-431
- Species or organism
- Human
- Tissue
- Skin
- Knockout validation
- Next Generation Sequencing, Western blot
- Mutation description
- Knockout achieved by CRISPR/Cas9 X = 5 bp deletion Frameshift: 100%
- Disease
- Epidermoid Carcinoma
- Concentration
Properties
- Gene name
- KRT13
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Next Generation Sequencing, Western blot
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
Cytokeratin 13 also known as KRT13 or CK13 is a type I intermediate filament protein weighing approximately 44 kDa. It is one of the cytokeratin types that plays a critical role in the mechanical stability and integrity of epithelial cells. Cytokeratin 13 is expressed in the stratified squamous epithelium particularly in the upper layers of non-cornified epithelia which include the esophagus tongue and cervix. This protein forms heteropolymers with type II keratins contributing to the cytoskeletal filament network within epithelial cells.
- Biological function summary
This protein participates in maintaining the structural framework and dynamics within epithelial tissues. As part of the cytoskeletal complex cytokeratin 13 supports cellular resilience against mechanical stress. It interacts with other cytokeratins contributing to the formation of a robust keratin filament network essential for epithelial cell function and differentiation. Its expression and regulation are key to the homeostasis of the tissues where it is found ensuring proper cell division and tissue integrity.
- Pathways
Cytokeratin 13 integrates into epithelial cell differentiation and repair processes. It is involved in the epithelial-mesenchymal transition (EMT) pathway important for tissue development wound healing and cancer metastasis. During the EMT process cytokeratin 13 often works alongside proteins like E-cadherin and Vimentin mediating changes in epithelial cell architecture and polarity. This modulation is essential for cellular plasticity and response to environmental cues.
- Associated diseases and disorders
Cytokeratin 13 has associations with certain epithelial tissue abnormalities such as oral squamous cell carcinoma and a subgroup of inherited blistering diseases like epidermolysis bullosa. In oral squamous cell carcinoma dysregulation of cytokeratin 13 expression may indicate tumor progression and metastasis. In epidermolysis bullosa mutations affecting keratin interactions including those with other keratins like cytokeratin 14 can lead to fragile skin and mucosal surfaces resulting in increased susceptibility to physical damage and impaired healing.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
4 product images
Western blot - Human KRT13 knockout A-431 cell lysate (ab269647)
False colour image of Western blot: Anti-Cytokeratin 13 antibody [EPR3671] staining at 1/100000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-Cytokeratin 13 antibody [EPR3671] ab92551 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line Human KRT13 knockout A-431 cell line ab269483 (knockout cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
Western blot - Human KRT13 knockout A-431 cell lysate (ab269647)
False colour image of Western blot: Anti-Cytokeratin 13 antibody [AE8] staining at 1 μg/ml, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-Cytokeratin 13 antibody [AE8] ab16112 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line Human KRT13 knockout A-431 cell line ab269483 (knockout cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/20000 dilution.
Western blot - Human KRT13 knockout A-431 cell lysate (ab269647)
False colour image of Western blot: Anti-Cytokeratin 13 antibody [EPR3672] staining at 1/2000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (Anti-GAPDH antibody [6C5] - Loading Control ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-Cytokeratin 13 antibody [EPR3672] ab133340 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line Human KRT13 knockout A-431 cell line ab269483 (knockout cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) at 1/20000 dilution.
Next Generation Sequencing - Human KRT13 knockout A-431 cell lysate (ab269647)
Knockout achieved by CRISPR/Cas9; X = 5 bp deletion; Frameshift: 100%
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com